Trial Profile
Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: A phase II randomized study by the UNICANCER with cooperation of AFSOS
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Nov 2023
Price :
$35
*
At a glance
- Drugs Riluzole (Primary)
- Indications Peripheral neuropathies
- Focus Therapeutic Use
- Acronyms RILUZOX-01
- 07 Nov 2023 Planned End Date changed from 28 Apr 2024 to 28 Oct 2024.
- 07 Nov 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2024.
- 07 Nov 2023 Status changed from recruiting to active, no longer recruiting.